ENDPOINTS

Start of 2025 comes with generic drug price decreases, ...

More generic drug prices decreased than increased in January, a new report from ...

FDA approves Neurotech therapy for rare eye disease 

The FDA on Thursday approved Neurotech Pharmaceuticals’ cell therapy for an eye ...

Bayer eyes capital raise as it grapples with Monsanto c...

Bayer is asking shareholders to authorize a potential equity offer that would al...

How bluebird's buyout offer went from $100M upfront to ...

Bluebird bio went from a high-flying $10 billion company in 2018 during the heyd...

What FDA, NIH hearings say about Trump drug, health policy

President Donald Trump's nominees for NIH director and FDA commissioner sailed t...

At $300M Kardigan startup, former MyoKardia team unveil...

When some former MyoKardia execs reunited with $300 million for a new "heart hea...

Jeb Keiper steps down from Nimbus CEO post, business ch...

Nimbus Therapeutics is getting a new CEO after more than six years, as Jeb Keipe...

CytomX, Amgen pass on T cell engager; Molecular Partner...

Plus, news about Atea Pharmaceuticals: CytomX, Amgen stop work on T cell eng...

Roche launches new research center with Harvard in Bost...

Roche announced a new research hub on Friday in partnership with Harvard that it...

Tune’s CEO search ends as John McHutchison takes top sp...

John McHutchison started Monday as CEO and chairman of Tune Therapeutics, after ...

J&J axes Phase 3 depression program due to ‘insufficien...

Johnson & Johnson scrapped its Phase 3 program for aticaprant, an experimental a...

Walgreens to go private in $10B deal

Walgreens is entering a new chapter as it agrees to sell itself to a private equ...

Moderna stands by its Covid vaccine patents after PTAB ...

Moderna says its long-running patent dispute with Pfizer and BioNTech isn't over...

Healthcare is bullish on AI

It’s only been about two years since healthcare really started adopting generati...

Corrected: Merck KGaA’s mixed Phase 2 lupus results; Zy...

Plus, news about Tris Pharma and ARS Pharmaceuticals: Merck KGaA’s lupus dru...

CordenPharma’s €100M investment top-up; Cytiva to lay o...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential ne...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.